Indication
Hematopoietic stem cell transplantation
4 clinical trials
7 products
1 drug
Clinical trial
A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap SyndromesStatus: Recruiting, Estimated PCD: 2025-02-01
Product
VenetoclaxProduct
FludarabineProduct
BusulfanProduct
AzacitidineProduct
Decitabine/cedazuridineClinical trial
Antigen Specific Adoptive T Cell Therapy for Opportunistic Cytomegalovirus Infection Occurring After Stem Cell TransplantStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Pilot Study of Transplant-related Events in Patients Receiving Ultra-high-dose Vitamin D SupplementationStatus: Completed, Estimated PCD: 2020-05-10
Drug
Vitamin D3Clinical trial
Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)Status: Recruiting, Estimated PCD: 2026-04-15
Product
TRX103